Organization (Other)
Teva Pharmaceuticals USA
ClinicalTrials.gov lists Teva Pharmaceuticals USA as lead sponsor of 176 trials. It has 10 active development programs and 56 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Teva Pharmaceuticals USA: 176 lead-sponsored trials and 0 legal-entity registrations. Part of TEVA PHARMACEUTICAL INDUSTRIES LTD.
Disease areas (57)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Asthma | 10 |
| Multiple Sclerosis | 7 |
| Leukemia, Myeloid, Acute | 5 |
| Migraine Disorders | 4 |
| Breast Neoplasms | 3 |
Showing 5 of 57 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 5 |
| 2016 | 7 |
Showing 10 of 26 years.
Recruitment duration, a model prediction: none of the 176 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (10)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| FLUTICASONE PROPIONATE | Rhinitis, Allergic | Phase 3 | 1 |
| Trifarotene | Acne Vulgaris | Phase 3 | 1 |
| Trifarotene 0.005 % Topical Cream | Acne Vulgaris | Phase 3 | 1 |
| DENOSUMAB | Bone Diseases, Metabolic | Phase 3 | 1 |
| DENOSUMAB | Osteoporosis | Phase 3 | 1 |
Showing 5 of 10 active programs.
Approved assets (56)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Estradiol | 1 |
| Diclofenac | 1 |
| DENOSUMAB | 1 |
| Trifarotene | 1 |
| Tapinarof | 1 |
Showing 5 of 56 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 83% hit target (n=6) | 60% on time (n=5) |
Journals published in (76)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 6 |
| American journal of respiratory and critical care medicine | 5 |
| Blood | 5 |
| Bone marrow transplantation | 5 |
| British journal of haematology | 4 |
Showing 5 of 76 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 11 | 1 | 2023-11-28 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Fairfield, US | FDA, Health Canada | Teva Pharmaceuticals USA |
| Teva Pharmaceuticals USA | Mexico, US | Health Canada | Teva Pharmaceuticals USA |
| Teva Pharmaceuticals USA | Greensboro, US | Health Canada | Teva Pharmaceuticals USA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Fondazione Policlinico Universitario Campus Bio-Medico | Co sponsors trial with | 1 |
Latest dated events (244)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-12-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-10-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-11-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 244 events.
Biomarker capability evidence (214)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 214 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.